Gastrointestinal Cancer | Specialty

Biology and Location of Gastroesophageal Cancers

June 20th 2017

Current Molecular Profiling in Gastric Cancers

June 20th 2017

Global Trends in Gastroesophageal Cancers

June 20th 2017

Dr. Diaz on Pembrolizumab for CRC

June 20th 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the impact of pembrolizumab (Keytruda) in patients with colorectal cancer (CRC).

test-1

June 17th 2017

Dr. Bekaii-Saab on Napabucasin Plus Nab-paclitaxel/Gemcitabine in Pancreatic Cancer

June 16th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses a phase I study of napabucasin plus nab-paclitaxel (Abraxane) and gemcitabine for the treatment of patients with pancreatic cancer.

Hopeful Signs in Pancreatic Cancer

June 13th 2017

Although the prognosis for patients with pancreatic cancer is often grim, there have been noteworthy improvements in outcomes through the use of current chemotherapies.

Dr. Fuchs Discusses Immunotherapy in Gastric Cancer

June 13th 2017

Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.

Phase III MABp1 Colorectal Cancer Study Discontinued

June 13th 2017

Following a second prospectively planned, unblinded analysis, drug manufacturer XBiotech has cancelled the phase III XCITE study of MABp1 (Hutruo; formerly Xilonix) in patients with advanced colorectal cancer.

Dr. Bekaii-Saab on Results of the IDEA Project for Colon Cancer

June 9th 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the results of the phase III IDEA project for patients with stage III colon cancer.

Dr. Kelley on the Development of Biomarkers for HCC

June 8th 2017

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).

Dr. Shah on Risk Factors for Early-Onset CRC

June 8th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses risk factors for patients with early-onset colorectal cancer (CRC).

Neoadjuvant Imatinib Associated With High Rate of R0 Resection in Large Gastric GIST

June 8th 2017

Investigators conducting a small multinational study in Asian patients have concluded that 6 to 9 months of treatment with neoadjuvant imatinib is a promising treatment for patients with large gastric gastrointestinal stromal tumors.

Pembrolizumab Gastric Cancer Data Updated, as FDA Considers Approval

June 5th 2017

Pembrolizumab continued to show promising signs of clinical activity as a treatment for patients with advanced gastric or gastroesophageal junction cancer in updated findings from the KEYNOTE-059 study.

Study Backs 50% Chemo Cutback After Surgery for Low-Risk Colon Cancer

June 4th 2017

Most patients with low-risk advanced colon cancer would benefit from a 50% reduction in the oxaliplatin-containing chemotherapy they typically receive after surgery without notably increasing their risk of recurrence and while markedly decreasing the likelihood that they will develop neuropathy, according to an analysis that challenges the current standard of care and paves the way for a more personalized approach.

Lenvatinib OS Noninferior, PFS Improved Versus Sorafenib for Unresectable HCC

June 4th 2017

First-line treatment with lenvatinib (Lenvima) improved progression-free survival by 3.7 months and was noninferior for overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma.

Fear of Recurrence and Anxiety Lowered in Cancer Survivors After Psychological Intervention

June 3rd 2017

Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.

Expert Discusses Choice Between Immunotherapy and TKIs for HCC

May 31st 2017

Physicians treating hepatocellular carcinoma often have to choose between a tyrosine kinase inhibitor (TKI) and immunotherapy but oncologists need better tools to make an informed choice.

Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma

May 31st 2017

Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma.

Uridine Triacetate for 5-FU or Capecitabine Toxicity

May 30th 2017